Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
2.964 Leser
Artikel bewerten:
(2)

MEI Micro, Inc.: MEI Micro partners with Steadman Philippon Research Institute in new technology development

SANTA BARBARA, Calif., June 26, 2025 /PRNewswire/ -- MEI Micro, Inc. is partnering with Steadman Philippon Research Institute (SPRI) to develop new technology and product platforms that will help establish new standards in accuracy and precision for a number of applications related to MedTech, healthcare, sports medicine and athletic performance.

MEI Micro and The Steadman Phillippon Research Institute

The partnership will bring together MEI's expertise in next-generation MEMs inertial sensor technology and the deep subject matter expertise of SPRI, one of the world's leading Institutes of orthopaedics and sports medicine research. The focus will include the development of smart surgical tools, medical-grade wearables and motion capture systems for the assessment and continuous monitoring of patients, athletes and military personnel. These systems will feature MEI's proprietary 3DS MEMs platform technology which is 80x-100x more accurate than existing consumer- and industrial-grade MEMs inertial sensors currently in use in life science applications including consumer wearables like smart watches and rings.

"There is tremendous potential in this innovative partnership between MEI Micro and SPRI," shared Marc J. Philippon, MD, Managing Partner of The Steadman Clinic and Chairman of SPRI. "Harnessing MEI's technology will enable us to develop new products for surgical advancement while enhancing the patient's recovery experience through next-generation technology."

MEI Micro recently began shipping first commercial product samples of its industry first navigation-grade, multi-axis chip scale 3 degrees of freedom (DoF) MEMs accelerometer platform, which received the Most Innovative Product Award for MEMs at the 2024 Sensors Converge conference. At this year's event, CEO Louis Ross will present "Next Generation MEMS Inertial for Life Science Applications" and will review its plans to work closely with SPRI, which has a long history of developing leading-edge approaches to orthopaedic surgery and conducting research to support the care of some of the world's top professional athletes and the U.S. Olympic and Paralympic teams.

"We look to democratize the use of high-accuracy inertial data", said Ross, which includes delivering the highest accuracy, lowest cost, size, weight and power (CSWaP) sensors to be put on the market. "The need for much higher accuracy has been accelerated due to the broad-spread application of artificial intelligence and machine learning, especially at the EDGE, which includes the Internet of Medical Things (IoMT)." EDGE computing, also referred to as "TinyML", requires higher accuracy data in order to develop more efficient sensor fusion software and advanced algorithms that can become a catalyst for preventative, predictive and personalized healthcare and related assessments and medical treatments. MEMs inertial sensors also provide the ability to continuously track and monitor users, providing a key enabler for telemedicine/telehealth which will lead to lower costs for clinical trials and healthcare in general.

"SPRI's partnership with MEI Micro will result in the development of a portfolio of healthcare technological advancements," said Dan Drawbaugh, CEO of SPRI. "As SPRI expands its artificial intelligence and machine learning capabilities, there is a natural synergy with MEI Micro's technologies for precision-based solutions. We look forward to working with MEI Micro to change the shape of personalized healthcare on a global scale."

The organizations plan to develop new technology products, including targeted orthopaedic and sports medicine applications for individual joints, with the ultimate goal of advancing patient treatment, care and recovery.

MEI Micro, Inc. is a technology start up commercializing the world's first tactical to navigation grade capable, multi-axis, chip scale MEMs inertial sensor systems. The company's 3DS proprietary MEMs platform technology includes MEMs manufacturing process, advanced semiconductor packaging, MEMs device design and applications related intellectual property. The company works closely with partners to develop custom, application specific solutions enabled by its 3DS MEMs inertial measurement units (IMUs) and inertial navigation systems (INSs).

Steadman Philippon Research Institute (SPRI) is dedicated to keeping people of all ages physically active through orthopaedic research and education. With an enduring focus on applied clinical translation, SPRI is dedicated to discovering new therapies, treatments and cures that can be brought to patients in a clinical setting. SPRI utilizes the latest regenerative medicine techniques-basic science studies at the cellular level-to investigate the causes and effects of degenerative arthritis, techniques of musculoskeletal regeneration and healing processes. SPRI also uses state-of-the-art Biomotion and Robotics technologies, magnetic resonance imaging and over 35 years of patient outcomes data in its bench-to-bedside approach to research. The 501(c)(3) charitable organization is one of the most published organizations in sports medicine research and education.

Logo - https://mma.prnewswire.com/media/2719617/MEI_COMBO_LOGO.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/mei-micro-partners-with-steadman-philippon-research-institute-in-new-technology-development-302492060.html

© 2025 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.